Cargando…
Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
Various c-mesenchymal-to-epithelial transition (c-MET) inhibitors are effective in the treatment of non-small cell lung cancer; however, the inevitable drug resistance remains a challenge, limiting their clinical efficacy. Therefore, novel strategies targeting c-MET are urgently required. Herein, th...
Autores principales: | Li, Pengyun, Jia, Changkai, Fan, Zhiya, Hu, Xiaotong, Zhang, Wenjuan, Liu, Ke, Sun, Shiyang, Guo, Haoxin, Yang, Ning, Zhu, Maoxiang, Zhuang, Xiaomei, Xiao, Junhai, Zheng, Zhibing, Li, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326257/ https://www.ncbi.nlm.nih.gov/pubmed/37425039 http://dx.doi.org/10.1016/j.apsb.2023.01.014 |
Ejemplares similares
-
Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism
por: Li, Pengyun, et al.
Publicado: (2022) -
Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
por: Sachkova, Anastasia A., et al.
Publicado: (2022) -
Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups
por: Jiang, Yingnan, et al.
Publicado: (2016) -
Discovery of
a Highly Potent and Selective Dual PROTAC
Degrader of CDK12 and CDK13
por: Yang, Jianzhang, et al.
Publicado: (2022) -
HGF–Met Pathway in Regeneration and Drug Discovery
por: Matsumoto, Kunio, et al.
Publicado: (2014)